Ophthalmology Prior Authorization Automation: Enhance Efficiency in Eye Care

High-Volume Prior Authorization Categories in Ophthalmology

Ophthalmology practices frequently encounter prior authorization requirements for a range of specialized treatments and diagnostics. These often include chronic conditions requiring ongoing management and procedures with specific coverage criteria. Understanding these categories is critical for proactive PA management.

Key PA-Triggering Services and Treatments

• **Anti-VEGF Intravitreal Injections:** A high-volume category including Aflibercept (Eylea, Eylea HD), Ranibizumab (Lucentis, Cimerli, Byooviz), Faricimab (Vabysmo), Brolucizumab (Beovu), and Bevacizumab, for indications like wet AMD, DME, and RVO.
• **Cataract Surgery with Premium IOLs:** While standard cataract procedures often bypass PA, premium intraocular lenses or specific lens technologies frequently require pre-approval.
• **Glaucoma Surgical Procedures:** This encompasses micro-invasive glaucoma surgery (MIGS), traditional trabeculectomy, and tube shunt procedures, each with varying payer policies.
• **Corneal Procedures:** Such as DSAEK, DMEK endothelial keratoplasty, corneal cross-linking for keratoconus, and refractive surgery when medically indicated.
• **Oculoplastic Procedures:** Including blepharoplasty for visual-field-affecting ptosis, ectropion/entropion repair, and lacrimal procedures, often requiring careful medical necessity documentation.

Critical Documentation Requirements for Ophthalmology PA

Payer policies for ophthalmology procedures are often stringent, aligning closely with clinical guidelines such as the AAO Preferred Practice Patterns [aao-guidelines]. Complete and accurate documentation is paramount to secure timely approvals. Klivira's platform is designed to support these detailed requirements.

Essential Documentation Elements for Approval

• **For Anti-VEGF Injections:** Diagnosis confirmation (e.g., OCT showing fluid), visual acuity, prior treatment response (for ongoing cycles), and step therapy compliance for biosimilar substitution.
• **For Premium IOLs:** Patient acknowledgment of out-of-pocket costs and clear medical necessity for specific specialty lenses.
• **For Glaucoma Surgery:** Documented IOP despite maximal medical therapy, visual field documentation, and a prior trial of medications.
• **For Corneal Cross-linking:** Diagnosis of keratoconus with documented progression.
• **For Functional Blepharoplasty:** Visual field tests demonstrating a field defect and supporting photographs.

Common Denial Reasons in Ophthalmology Prior Authorization

Despite diligent efforts, ophthalmology practices frequently encounter denials due to specific documentation gaps or policy nuances. These denials often stem from issues related to biosimilar mandates, incomplete treatment histories, or mischaracterization of medical necessity. Klivira helps mitigate these common pitfalls.

Frequent Triggers for Prior Authorization Denials

• **Biosimilar Substitution:** Denials for brand-name anti-VEGF medications when a biosimilar is mandated by payer policy.
• **Prior-Treatment Response Gaps:** Insufficient documentation of patient response to previous anti-VEGF cycles.
• **Cosmetic vs. Medical Determination:** Lack of clear medical necessity documentation for oculoplastic procedures like blepharoplasty.
• **Visual Field Documentation Gaps:** Inadequate visual field testing or reporting for conditions such as ptosis repair or glaucoma surgery.
• **MIGS-Specific Constraints:** Payer policies often have highly specific criteria for micro-invasive glaucoma surgery device approval, leading to denials if not met.

Klivira's Solution for Ophthalmology Prior Authorization Automation

Klivira’s platform is purpose-built to address the unique workflow constraints and PA challenges within ophthalmology. Our automation capabilities streamline the most demanding aspects of eye care prior authorization, from chronic injection cycles to complex surgical pre-approvals, integrating directly with your EMR.